Company Overview
Corbus Pharmaceuticals Holdings, Inc. operates as a clinical stage biotechnology enterprise dedicated to the development and commercialization of therapeutics targeting cancer and obesity. The company functions within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a reliance on advanced research and development to generate pipeline assets for potential market approval. The firm currently maintains a market capitalization of $147.39M and employs a workforce of 36 individuals. These valuation and staffing metrics indicate that Corbus is a small-cap entity with a lean operational structure, suggesting that its value is primarily derived from the potential future success of its specific therapeutic pipeline rather than established commercial revenue streams.
Financial Health
The company reports a Net Income of $-78,537,000 and an EBITDA of $-85,077,000 for the trailing twelve months, while annual revenue figures are not reported as a distinct positive value in the available data. The substantial gap between revenue and net income, alongside the negative EBITDA, reveals a cost structure dominated by high research and development expenditures typical of clinical stage biotechnology firms, where costs are incurred before product commercialization. Free cash flow stands at $-37,728,752, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity from current operations. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which reflects the accounting treatment of net losses against zero or nominal revenue, signifying that the company has not yet achieved profitability. The balance sheet shows a significant cash reserve of $163.27M compared to total debt of $1.63M, resulting in a debt-to-equity ratio of 1.11. Despite the elevated debt-to-equity figure, the liquidity position is heavily weighted toward cash holdings, suggesting the company is not leveraged in a manner that poses immediate solvency risks given the low absolute debt level. The Current Ratio is 8.07, a figure that indicates robust short-term liquidity and a substantial ability to cover current liabilities with current assets. Return on Equity is -54.2% and Return on Assets is -32.9%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common phase for early-stage development companies.
Valuation Assessment
The company presents a Trailing P/E Ratio (TTM) that is not available, while the Forward P/E is listed as -1.68, implying that the market prices the stock based on expected future earnings that are anticipated to remain negative. The Price to Book ratio is 0.99, indicating that the market values the company at roughly equal to its book value rather than at a premium or discount relative to its tangible assets. Price to Sales is not available, and the EV/EBITDA stands at 0.17, suggesting a valuation metric that is heavily influenced by the company's negative earnings and the specific way enterprise value is calculated when earnings are negative. The stock has traded between a 52-Week High of $20.56 and a 52-Week Low of $4.64, providing a historical range within which the current price fluctuates. The Beta value is 2.91, which means the stock price is highly volatile and expected to move with significantly greater intensity than the broader market index, reflecting the high risk associated with clinical stage biotechnology equities.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning historical growth rates cannot be calculated from the provided annual data. Since the company does not generate positive earnings or revenue growth in the traditional sense, it does not pay a dividend, resulting in a Dividend Yield of N/A and a Payout Ratio of 0.0%. Consequently, the company does not distribute income to shareholders but instead retains its earnings to fund ongoing research and development efforts necessary to advance its pipeline. The overall growth and income profile for Corbus Pharmaceuticals is characterized by a focus on capital deployment into future therapeutic assets rather than current profitability or income generation for investors.